Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Redemplo Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0773

    Hypertriglyceridemia - Redemplo

    Customize your policy alerts

    Sign up for Cigna Policy IP0773 alerts

    Get alerted when Policy IP0773 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Redemplo (plozasiran subcutaneous injection) in adults with familial chylomicronemia syndrome. It applies to health benefit plans administered by Cigna Companies, subject to the applicable benefit plan terms and coverage mandates.

    Policy Summary
    PayerCigna
    PolicyHypertriglyceridemia - Redemplo
    Policy CodePolicy IP0773
    Change TypeMaterial revision
    Effective DateNov 15, 2026
    Last ReviewOct 15, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the baseline fasting triglyceride level before treatment with a triglyceride-lowering medication.
    SourceLink
    POLICY UPDATE CHANGES

    The approval duration for initial Redemplo therapy was changed from 1 year to 6 months.

    Continuation therapy was added for patients currently receiving Redemplo who have experienced a response to therapy.

    The preferred-product requirement for a prior Tryngolza trial was removed.

    The terminology describing decreased platelets was replaced with thrombocytopenia.

    ≥18 yearsMinimum age for initial therapy
    ≥880 mg/dLRequired baseline fasting triglyceride level
    ≤20 g/dayRecommended low-fat diet with Redemplo

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsInitial approval duration
    1 yearContinuation approval duration
    ≥10 or ≥45FCS diagnostic score thresholds

    Coverage Criteria

    Familial Chylomicronemia Syndrome

    Covered for the FDA-approved indication when the patient meets ONE of the following pathways.

    FDA-approved FCS coverage pathways

    • Initial Therapy

      • Adult patient and triglyceride threshold: The patient is at least 18 years old and has a baseline fasting triglyceride level of at least 880 mg/dL before treatment with a triglyceride-lowering medication.Age ≥18; fasting TG ≥880 mg/dL

        Baseline triglyceride documentation is required.

      • Qualifying FCS diagnosis

        • Molecular genetic confirmation: Molecular genetic test results demonstrate biallelic pathogenic variants in at least one gene causing FCS.Biallelic pathogenic variant(s)

          Documentation required. Examples include LPL, GPIHBP1, APOA5, APOC2, or LMF1.

        • Inconclusive genetic testing with qualifying score: Molecular genetic test results are inconclusive and the patient has either a Moulin FCS score of at least 10 or a North American FCS score of at least 45.Moulin ≥10 or NAFCS ≥45

          Documentation required.

        • Clinical FCS diagnosis

          • Qualifying clinical history: History of acute pancreatitis not caused by alcohol or cholelithiasis, or recurrent hospitalizations for severe abdominal pain without another explainable cause.1 of 2 history elements
          • No secondary hypertriglyceridemia: The patient does not have a secondary cause of hypertriglyceridemia, such as obesity or uncontrolled diabetes.Absent
          • Insufficient response to traditional therapy: The patient lacks response to a traditional triglyceride-lowering medication, such as a statin, niacin, fibrate, or omega-3 fatty acid.Lack of response
      • Diet and specialist prescribing: Redemplo will be used concomitantly with a low-fat diet, and it is prescribed by a cardiologist, endocrinologist, lipidologist, or physician focused on severe hypertriglyceridemia disorders.Low-fat diet; qualifying prescriber
    • Continuation Therapy: The patient is currently receiving Redemplo and has experienced a response to therapy; approve for 1 year.1 year

      Examples of response include lowering triglycerides or reducing the number of pancreatitis episodes.

    Redemplo is not medically necessary for hypertriglyceridemia when the patient does not have a confirmed diagnosis of familial chylomicronemia syndrome (FCS).

    Use of Redemplo for severe hypertriglyceridemia outside confirmed FCS is not medically necessary because Redemplo is not FDA-approved for this indication.

    Diagnostic and Treatment Thresholds

    Baseline fasting triglyceride level
    Required baseline levelFasting triglycerides ≥ 880 mg/dL
    Measurement timingMeasure at baseline before treatment with a triglyceride-lowering medication
    DocumentationDocumentation of the baseline level is required
    Moulin FCS score
    Qualifying thresholdMoulin FCS score ≥ 10
    Use in diagnosisApplies when molecular genetic test results are inconclusive
    Clinical significanceA score of at least 10 is a strong predictor of FCS

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization and Specialist Involvement

    Prior authorization is required for benefit coverage of Redemplo. Initial approval requires the medication to be prescribed by, or prescribed in consultation with, a physician who specializes in the condition being treated.

    Documentation Required

    Required Supporting Documentation

    Submit patient-specific supporting documentation wherever the criteria identify that documentation is required. Acceptable evidence may include chart notes, laboratory tests, medical test results, claims records, prescription receipts, and other relevant information; all documentation must include patient-specific identifying information.

    • Include documentation supporting the applicable diagnosis, baseline laboratory values, genetic or diagnostic evidence, and treatment response.
    • Ensure every submitted record contains patient-specific identifying information.

    Clinical Background

    Familial chylomicronemia syndrome (FCS) is an ultra-rare genetic form of severe hypertriglyceridemia caused by biallelic pathogenic variants in genes involved in triglyceride metabolism. Patients may have triglyceride levels in the thousands and are at risk for severe abdominal pain, recurrent acute pancreatitis, eruptive xanthomas, and lipemia retinalis. Redemplo is used as an adjunct to diet to reduce triglycerides in adults with FCS; a low-fat diet of no more than 20 grams of fat per day is recommended.

    Definitions

    Familial chylomicronemia syndrome (FCS)
    DefinitionFCS is an ultra-rare genetic form of severe hypertriglyceridemia
    Genetic basisCaused by biallelic pathogenic variants in an FCS-associated gene
    Associated genesLPL, GPIHBP1, APOA5, APOC2, and LMF1
    Clinical contextPatients may have triglyceride levels in the thousands and risk severe abdominal pain, acute pancreatitis, eruptive xanthomas, and lipemia retinalis
    Severe hypertriglyceridemia
    Severe levelTriglyceride levels above 500 mg/dL are categorized as severe hypertriglyceridemia
    Normal level

    Initial Therapy

    Initial Therapy

    Approve for 6 months when ALL initial-therapy requirements are met.

    • Age and triglyceride level: The patient is at least 18 years old and has a baseline fasting triglyceride level of at least 880 mg/dL before treatment with a triglyceride-lowering medication.Age ≥18; fasting TG ≥880 mg/dL

      Documentation required for the baseline triglyceride level.

    • FCS diagnostic evidence

      • Genetic confirmation: Molecular genetic testing demonstrates biallelic pathogenic variants in at least one gene causing FCS.Biallelic pathogenic variant(s)

    Continuation Therapy

    Continuation Therapy

    Approve for 1 year when the patient is currently receiving Redemplo and has experienced a response to therapy.

    • Current treatment: The patient is currently receiving Redemplo.Currently receiving
    • Treatment response: The patient has experienced a response to Redemplo, such as lower triglycerides or fewer pancreatitis episodes.Documented response
    Policy Summary
    PayerCigna
    PolicyHypertriglyceridemia - Redemplo
    Policy CodePolicy IP0773
    Change TypeMaterial revision
    Effective DateNov 15, 2026
    Last ReviewOct 15, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of the baseline fasting triglyceride level before treatment with a triglyceride-lowering medication.
    SourceLink
    On This Page
    Coverage CriteriaDiagnostic and Treatment ThresholdsPrior Authorization and DocumentationClinical BackgroundDefinitionsInitial TherapyContinuation Therapy
    North American FCS score
    Qualifying thresholdNorth American FCS score ≥ 45
    Use in diagnosisApplies when molecular genetic test results are inconclusive
    Clinical significanceA score of at least 45 makes classical FCS very likely
    Low-fat diet
    Daily limitNo more than 20 grams of fat per day
    Use with RedemploMaintain the low-fat diet in conjunction with Redemplo
    Treatment roleRedemplo is used as an adjunct to diet to reduce triglycerides in adults with FCS
    Untreated FCS triglyceride characterization
    Untreated triglyceride levelFCS is characterized by triglycerides > 885 mg/dL in the untreated state
    Associated findingsPatients may experience incapacitating abdominal pain and severe recurrent acute pancreatitis
    Genetic associationPathogenic variants may occur in LPL, GPIHBP1, APOA5, APOC2, or LMF1
    FCS score diagnostic criterion
    Required triglyceride patternFasting triglycerides > 885 mg/dL for three consecutive blood analyses
    Testing intervalAnalyses must be measured at least 1 month apart
    Surrogate findingEruptive xanthoma may be used as a surrogate for high triglyceride levels
    FCS score treatment-response criterion
    Treatment-response thresholdTriglyceride decrease < 20% with hypolipidemic treatment
    Scoring useNo response to hypolipidemic treatment contributes to the FCS score
    Treatment examplesHypolipidemic treatment may include statins, niacin, fibrates, or omega-3 fatty acids
    Documentation Required

    Document Baseline Triglycerides

    For initial therapy, submit documentation of a fasting triglyceride level of at least 880 mg/dL at baseline, measured before treatment with a triglyceride-lowering medication.

    • Baseline means the value before treatment with a triglyceride-lowering medication.
    • Examples include statins, niacin, fibrates, and omega-3 fatty acids.
    Documentation Required

    Genetic or Diagnostic Evidence of FCS

    When applicable, submit qualifying molecular genetic test results supporting familial chylomicronemia syndrome (FCS).

    • Document biallelic pathogenic variants in at least one FCS-associated gene.
    • Examples include LPL, GPIHBP1, APOA5, APOC2, and LMF1.
    • If genetic testing is inconclusive, document either a Moulin FCS score of ≥ 10 or a North American FCS score of ≥ 45.
    Documentation Required

    Clinical FCS Diagnosis

    If genetic confirmation is unavailable or inconclusive, document a clinical diagnosis of FCS supported by the required clinical history and treatment findings.

    • Document a history of acute pancreatitis not caused by alcohol or cholelithiasis, or recurrent hospitalizations for severe abdominal pain without another explainable cause.
    • Document absence of secondary hypertriglyceridemia, such as from obesity or uncontrolled diabetes.
    • Document lack of response to a traditional triglyceride-lowering medication.
    Documentation Required

    Document Response for Continuation

    For continuation therapy, document that the patient has experienced a response to Redemplo. Approval may be supported by reduced triglyceride levels or fewer pancreatitis episodes.

    • Continuation approval is for 1 year when response to therapy is demonstrated.
    Denial Risk

    Use Without Confirmed FCS

    Redemplo is not medically necessary for hypertriglyceridemia when the patient does not have a confirmed diagnosis of familial chylomicronemia syndrome.

    • Requests for severe hypertriglyceridemia alone are not covered under this indication because Redemplo is not FDA-approved for that use.
    Denial Risk

    Failure to Meet Initial-Therapy Criteria

    Initial therapy may be denied when required eligibility and diagnostic criteria are not met or documented.

    • Patient must be at least 18 years of age.
    • Baseline fasting triglycerides must be ≥ 880 mg/dL before triglyceride-lowering treatment.
    • Required genetic evidence, qualifying FCS scores, or the complete clinical FCS diagnosis must be documented.
    • The medication must be used with a low-fat diet and prescribed by a cardiologist, endocrinologist, lipidologist, or physician focused on severe hypertriglyceridemia.
    Denial Risk

    No Documented Response for Continuation

    Continuation therapy may be denied when the record does not demonstrate a response to Redemplo.

    • Document evidence such as lowered triglycerides or a reduced number of pancreatitis episodes.
    Denial Risk

    Unsupported Claim or Documentation

    Claims may be denied when submitted without covered diagnosis and/or procedure codes or without the documentation required by the policy criteria.

    • Use the most appropriate codes in effect on the submission date.
    • Services billed for diagnoses not covered under the policy, or claims not accompanied by covered codes, are not reimbursable.
    • Include all required patient-specific supporting documentation.
    Normal triglyceride levels are below 150 mg/dL
    FCS contextPatients with FCS may have triglyceride levels in the thousands
    Moulin FCS score
    Scoring methodThe FCS score is the sum of specified clinical and laboratory criteria
    ThresholdA score ≥ 10 suggests that FCS is very likely
    Diagnostic contextThe score includes clinical and laboratory findings such as triglyceride levels, pancreatitis history, abdominal pain, and treatment response
    NAFCS score
    Full nameNorth American Familial Chylomicronemia Syndrome score
    ThresholdA score ≥ 45 indicates that classical FCS is very likely
    UseThe score is used as part of FCS diagnosis and identification
    Inconclusive genetic testing: Genetic testing is inconclusive and the patient has a Moulin FCS score of at least 10 or a North American FCS score of at least 45.Moulin ≥10 or NAFCS ≥45
  1. Clinical diagnosis: The patient has a qualifying history of acute pancreatitis not caused by alcohol or cholelithiasis or recurrent hospitalization for severe unexplained abdominal pain, absence of secondary hypertriglyceridemia, and lack of response to traditional triglyceride-lowering medication.All 3 elements
  2. Diet and prescriber: Redemplo will be used concomitantly with a low-fat diet and is prescribed by a cardiologist, endocrinologist, lipidologist, or physician who focuses on disorders related to severe hypertriglyceridemia.Low-fat diet; qualifying specialist